Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patient with clinical and pathological diagnoses of severe cutaneous adverse drug reactions such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis or Durg reaction with eosinophilia and systemic symptoms.~2. Male or female patient aged more than 4 years.~3. Inform consent obtained.~Exclusion Criteria:~1. Pregnant or breastfeeding female.~2. Allergic to any anti-TNF-α biological product.~3. Active or latent tuberculosis confirmed with Chest X-ray.~4. Severe active infection and septicemia.~5. Active Hepatitis B or C carrier.~6. Suspected HIV carrier with CD4 count less than 200.~7. Patient with poor compliance or with safety concerns judged by investigator.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anti- TNF-a treatment (Type: EXPERIMENTAL): 1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~2. Fill out the case report form~3. Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~4. Etanercept administration:~The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
- control group (Type: ACTIVE_COMPARATOR): 1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~2. Fill out the case report form~3. Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~4. Drug administration:~The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).